Areas of Focus

Transforming Pulmonary Disease Outcomes

ProterixBio is currently developing disease management platforms for pulmonary diseases, with an initial focus on COPD. Additional areas of pulmonary research include CF (cystic fibrosis) and IPF (idiopathic pulmonary fibrosis). Chronic pulmonary diseases share some common disease processes. ProterixBio’s development strategy leverages this commonality in the design of our biomarker panels, clinical studies, and data analysis methods.

 
 
 

Multifaceted Pulmonary Diseases

Distinct causes – Common Pathways

Statistics below are for the US only

COPD Chronic Obstructive Pulmonary Disease

  • 11-13MM Diagnosed
  • 3rd Leading Cause of Death
  • $38B Cost 2012 >> $50B 2020
  • >50% of Direct Costs Due to Exacerbations
  • 20-25% 30-Day Hospital Readmission Rate

IPF Idiopathic Pulmonary Fibrosis

  • 106,000 Diagnosed
  • Median Survival 3-5 years

CF Cystic Fibrosis

  • 30,000 Diagnosed
  • Average Lifespan 37-40 years

Additional Areas of Interest

In addition to our pulmonary disease platform, we are also collaborating with researchers on projects in neurology and oncology, including an exciting grant awarded by the Michael J Fox Foundation (more info to be released soon).

Have interest in partnering with us?: